Apyx Medical Corp expected to post a loss of 18 cents a share - Earnings Preview

Apyx Medical

19/03/2024 13:13

* Apyx Medical Corp  APYX.OQ   APYX.O  is expected to show a
rise
in quarterly revenue when it reports  results on March 21 for
the period ending December 31 2023
    * The Clearwater Florida-based  company is expected to
report a
17.7% increase in revenue to $14.848 million from $12.61 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.The company's guidance on January 8 2024, for
the period ended December 31, was for revenue between $14.20
million and $14.60 million.
    * ​LSEG's mean analyst estimate for Apyx Medical Corp is for
a
loss of 18 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Apyx
Medical Corp
is $3.50​, above​ its last closing price of $1.77. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.12       -0.11      -0.13     Missed  -14.8
 Jun. 30 2023  -0.07       -0.07      -0.11     Missed  -58.5
 Mar. 31 2023  -0.16       -0.13      -0.10     Beat    25.9​
 Dec. 31 2022  -0.15       -0.14      -0.17     Missed  -19.3
 ​​Sep.        -0.15       -0.14      -0.17     Missed  -17.2
 30 2022                                                
 Jun. 30 2022  -0.19       -0.19      -0.16     Beat    14.7​
 Mar. 31 2022  -0.14       -0.15      -0.17     Missed  -15.9
 Dec. 31 2021  -0.10       -0.11      -0.06     Beat    45.5
 This summary was machine generated March 19 at 13:13 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)